Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 57 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: MPI Clear all
Recruiting No phase listed Observational

Clinical and Basic Investigations Into Congenital Disorders of Glycosylation

NCT04199000
View directory record Official record
Conditions
Congenital Disorders of Glycosylation
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
12
States / cities
San Diego, California • Aurora, Colorado • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 3, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Results available

An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)

NCT03354273
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
PET MPI, SPECT MPI, Pharmacological stress agents
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
37
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Sep 3, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Results available

Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

NCT00826280
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
regadenoson, overencapsulated caffeine, technetium, placebo
Drug · Radiation
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Huntsville, Alabama • La Mesa, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 3, 2026, 1:03 AM EDT
Not listed Phase 3 Interventional

Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer

NCT00002659
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cisplatin-e therapeutic implant
Drug
Lead sponsor
Matrix Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
26
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 3, 2026, 1:03 AM EDT
Terminated Not applicable Interventional Results available

Half-Dose Radiopharmaceutical in Wide Beam Reconstruction

NCT01499654
View directory record Official record
Conditions
Myocardial Infarction, Ischemic Heart Disease
Interventions
Half-dose of the Tc99-m sestamibi (Cardiolite)
Drug
Lead sponsor
Edwin Wu
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Sep 3, 2026, 1:03 AM EDT
Completed Phase 4 Interventional Results available

Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging

NCT01221272
View directory record Official record
Conditions
Myocardial Perfusion Imaging, Myocardial Ischemia
Interventions
Ranolazine, Placebo to match ranolazine, SPECT MPI, Exercise
Drug · Procedure · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
26
States / cities
Birmingham, Alabama • Imperial, California • Lincoln, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2014 · Synced Sep 3, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)

NCT01618669
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
Regadenoson, Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)
Drug · Procedure
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
60
States / cities
Mobile, Alabama • Fremont, California • Long Beach, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 3, 2026, 1:03 AM EDT
Terminated No phase listed Observational

Automated Myocardial Performance Index Using Samsung HERA W10

NCT04140669
View directory record Official record
Conditions
Twin to Twin Transfusion Syndrome, Congenital Diaphragmatic Hernia, Neural Tube Defects, Lower Urinary Tract Infection
Interventions
Automated Myocardial Performance Index (MPI)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Sep 3, 2026, 1:03 AM EDT
Completed No phase listed Observational

Dual Energy CT for Ischemia Determination Compared to "Gold Standard" Non-Invasive and Invasive Techniques

NCT02178904
View directory record Official record
Conditions
Ischemia
Interventions
CT and stress test
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
5
States / cities
Overland Park, Kansas • New York, New York • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Sep 3, 2026, 1:03 AM EDT
Not listed Phase 2 Interventional

Chemotherapy in Treating Patients With Liver Cancer

NCT00003044
View directory record Official record
Conditions
Liver Cancer
Interventions
cisplatin-e therapeutic implant
Drug
Lead sponsor
Matrix Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
2
States / cities
Baltimore, Maryland • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 3, 2026, 1:03 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy

NCT06814587
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Bypass Graft (CABG)
Interventions
Hyperpolarized 13C Pyruvate Magnetic Resonance Imaging (HP-13C MRI), [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), SPECT MPI (Single Photon Emission Computed Tomography Myocardial Perfusion Imaging)
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
20 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 3, 2026, 1:03 AM EDT
Completed Not applicable Interventional Results available

A Multifaceted Prompting Intervention for Urban Children With Asthma

NCT01105754
View directory record Official record
Conditions
Asthma
Interventions
Multifaceted Prompting Intervention MPI
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
2 Years to 12 Years
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 3, 2026, 1:03 AM EDT
Completed Not applicable Interventional Results available

The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI

NCT04316676
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PET-MPI Protocol, CT-MPI, Coronary CT angiography (CCTA) for CT-FFR calculation, Regadenoson
Diagnostic Test · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Sep 3, 2026, 1:03 AM EDT
Completed No phase listed Observational

Efficiency and Outcomes of Stress-Only Anger and D-SPECT Stress-Only SPECT MPI

NCT01373944
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Aspire Foundation
Other
Eligibility
18 Years to 90 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Kansas City, Missouri • Lee's Summit, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 22, 2013 · Synced Sep 3, 2026, 1:03 AM EDT
Withdrawn Not applicable Interventional

Effect of Soy Intake on Cardiovascular Disease Biomarkers in Subclinical Hypothyroid Participants

NCT02024906
View directory record Official record
Conditions
Cardiovascular Disease, Subclinical Hypothyroid
Interventions
soy protein isolate (SPI), milk protein isolate (MPI)
Dietary Supplement
Lead sponsor
Jill Hamilton-Reeves, PhD RD LD
Other
Eligibility
25 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2015 · Synced Sep 3, 2026, 1:03 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Myocardial Perfusion Imaging Galmydar Rest/Stress

NCT05625490
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ga-68 Galmydar, 13N-ammonia
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 3, 2026, 1:03 AM EDT
Completed Not applicable Interventional

Impact of Daily, Digital and Behavioral Tele-health Tapering Program for Perioperative Surgical Patients Exposed to Opioids and Benzodiazepines.

NCT04787692
View directory record Official record
Conditions
Elective Spine Surgery Receiving Pre and/or Postoperative Pain Control With Opioids
Interventions
Opioid and Benzodiazepine Naive-patients, Opioid and Benzodiazepine Tolerant-patients
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Sep 3, 2026, 1:03 AM EDT
Completed Not applicable Interventional

The Myeloma Pack: A Multi-Modality Educational Intervention Strategy to Engage Patients With Multiple Myeloma

NCT03777306
View directory record Official record
Conditions
Multiple Myeloma
Interventions
ARM A EARLY INTERVENTION GROUP, ARM B DELAYED INTERVENTION GROUP
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 3, 2026, 1:03 AM EDT
Withdrawn Phase 4 Interventional

The Impact of the Routine Aminophylline Administration Following Regadenoson Stress on SPECT Myocardial Perfusion

NCT01655524
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
ASSUAGE Protocol
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 3, 2026, 1:03 AM EDT
Terminated Phase 3 Interventional

Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI

NCT00990327
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Apadenoson SPECT-MPI, Adenosine SPECT-MPI
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
863 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
103
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Sep 3, 2026, 1:03 AM EDT
Terminated Phase 3 Interventional

A Comparison Study of Apadenoson and Adenosine to Treadmill Exercise Stress.

NCT00380198
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Apadenoson
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Timeline
2006
U.S. locations
42
States / cities
Huntsville, Alabama • Santa Rosa, California • Bridgeport, Connecticut + 38 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Sep 3, 2026, 1:03 AM EDT
Enrolling by invitation No phase listed Observational

Serial PET MPI in Patients Undergoing Cancer Treatment

NCT05913999
View directory record Official record
Conditions
Cancer, Chemotherapeutic Toxicity, Coronary Artery Disease, Coronary Microvascular Disease
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 3, 2026, 1:03 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Stress Induced Right Ventricular Uptake on Lexiscan Stress MPI

NCT01697995
View directory record Official record
Conditions
Increased Right Ventricular Radiotracer Uptake
Interventions
Not listed
Lead sponsor
Aiden Abidov
Other
Eligibility
18 Years to 89 Years
Enrollment
650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Sep 3, 2026, 1:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Fetal Cardiac Function Parameters and HbA1c As Screening for Gestational Diabetes Mellitus

NCT05019508
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Sep 3, 2026, 1:03 AM EDT